Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Anish Desai

Portland, OR Medical Doctor

NPI 1437610466 CMS profile 11555438

3181 Sw Sam Jackson Park Rd, # L-579, Portland, OR 97239

Open in the dashboard

General payments

$12,857

75 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anish Desai of Portland, OR is reported in the CMS Open Payments database as having received $12,857 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,912 37
2024 General $4,534 32
2023 General $1,410 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anish Desai
  • Oregon median
  • Middle half of Oregon
  • National median

In program year 2025, general payments to Anish Desai were reported at $6,912. Among 8,828 Oregon profiles paid that year, the median was $125 and the middle half received between $38 and $384.

Show as a table
Year Anish Desai Oregon median Middle half National median
2019 $0 $117 $35–$433 $163
2020 $0 $82 $25–$259 $114
2021 $0 $91 $27–$282 $132
2022 $0 $111 $35–$326 $149
2023 $1,410 $120 $38–$359 $160
2024 $4,534 $124 $39–$382 $164
2025 $6,912 $125 $38–$384 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Abbott Laboratories $5,852 37 payments
  2. Medtronic, Inc. $5,384 31 payments
  3. Boston Scientific Corporation $1,410 5 payments
  4. Novartis Pharmaceuticals Corporation $119 1 payment
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $92 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Travel and Lodging $7,889 26 payments
  2. Food and Beverage $4,356 46 payments
  3. Education $612 3 payments
Products named General payments · program years 2023–2025
  1. GALLANT $2,875 17 payments
  2. General - Therapies $1,410 5 payments
  3. ENSITE PRECISION Electrophysiology $1,206 14 payments
  4. Micra $952 10 payments
  5. ENSITE Electrophysiology $917 2 payments
  6. ENSITE PRECISION Structural Heart $574 2 payments
  7. ENSITE Structural Heart $280 2 payments
  8. ADVISA DR MRI SURESCAN $185 1 payment
  9. AURORA EV-ICD MRI SURESCAN $138 2 payments
  10. LEQVIO $119 1 payment
  11. Other $284 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

233

Median for Student in an Organized Health Care Education/Training Program: 43

Drug cost

$67,085

Median for Student in an Organized Health Care Education/Training Program: $442

Branded share of claims

33.5%

Median for Student in an Organized Health Care Education/Training Program: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $34,110
Jardiance Empagliflozin Brand 33 $31,481
Ezetimibe Generic 21 $546
Metoprolol Succinate Generic 23 $271
Carvedilol Generic 20 $195
Rosuvastatin Calcium Generic 22 $146
Furosemide Generic 26 $142
Atorvastatin Calcium Generic 12 $120
Amlodipine Besylate Generic 13 $51
Lisinopril Generic 18 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record